Covered recipient · General Payments record
JOHN H STRICKLER
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$69,997.83
56 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $48,711.53 | 21 |
| Travel and Lodging | $13,470.69 | 12 |
| Honoraria | $6,600.00 | 2 |
| Food and Beverage | $1,082.72 | 18 |
| Education | $67.00 | 1 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $65.89 | 2 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $27,404.93 | 21 |
| PFIZER INC. | $12,516.69 | 8 |
| Janssen Research & Development, LLC | $10,860.21 | 7 |
| Exelixis Inc. | $7,712.24 | 9 |
| E.R. Squibb & Sons, L.L.C. | $3,342.50 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $3,045.00 | 1 |
| Astellas Pharma Global Development | $1,741.06 | 1 |
| TAIHO ONCOLOGY, INC. | $1,724.00 | 2 |
| Bayer Healthcare Pharmaceuticals Inc. | $1,404.00 | 2 |
| GlaxoSmithKline, LLC. | $168.52 | 2 |
| Astellas Pharma Europe Ltd | $78.68 | 2 |
Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JOHN H STRICKLER
NPI 1265523377 · CMS profile ID 598917
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
DURHAM, NC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1265523377?year=2025&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JOHN H STRICKLER, NPI 1265523377, CMS profile ID 598917. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1265523377?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). JOHN H STRICKLER, NPI 1265523377, CMS profile ID 598917. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1265523377?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- JOHN H STRICKLER, NPI 1265523377, CMS profile ID 598917, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1265523377?year=2025&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
56 matching records · $69,997.83 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–56 of 56.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $143.00 | 02/28/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204429204 | CMS |
| ABBVIE INC. | $247.47 | 02/28/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1204429209 | CMS |
| TAIHO ONCOLOGY, INC. | $1,560.00 | 02/19/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211406556 | CMS |
| Janssen Research & Development, LLC | $60.21 | 02/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1173801679 | CMS |
| PFIZER INC. | $118.08 | 01/23/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1228946256 | CMS |
| TAIHO ONCOLOGY, INC. | $164.00 | 01/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211410526 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $3,509.76 | 3 |
| PY2025 | Principal investigator | $4,058,488.29 | 589 |
| PY2024 | Recipient | $10,108.75 | 6 |
| PY2024 | Principal investigator | $5,722,468.05 | 524 |
| PY2023 | Recipient | $869.51 | 6 |
| PY2023 | Principal investigator | $4,654,510.51 | 265 |
| PY2022 | Principal investigator | $1,919,878.43 | 77 |
| PY2021 | Recipient | $1,012.50 | 1 |
| PY2021 | Principal investigator | $3,398,972.39 | 80 |
| PY2020 | Principal investigator | $2,192,265.69 | 49 |
| PY2019 | Principal investigator | $1,276,540.75 | 71 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
592 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $550.00 | 12/31/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors with Azirkitug (ABBV-514) as a Single Agent and in Combination with Budigalimab or Bevacizumab | No dispute reported | 06/30/2026 | 1202534333 |
| Principal investigator 1 | ABBVIE INC. | $3,617.27 | 12/31/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1202535191 |
| Principal investigator 1 | ABBVIE INC. | $600.00 | 12/31/2025 | Non-covered Recipient Entity DUKE CANCER INSTITUTE (DCI) - DUKE CANCER CENTER | A Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 as Monotherapy and in Combination with Bevacizumab in Adult Subjects with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1202535193 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $3,888.00 | 12/30/2025 | Non-covered Recipient Entity Duke University , | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190329917 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $208.00 | 12/18/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367621 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 12/18/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367623 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $169.00 | 12/18/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367625 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $45.00 | 12/18/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367627 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $68.00 | 12/18/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367629 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $57.00 | 12/18/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367631 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $226.00 | 12/18/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367633 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $117.00 | 12/18/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367635 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $537.00 | 12/18/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367639 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $86.00 | 12/18/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367641 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $226.00 | 12/18/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367643 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,598.00 | 12/18/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367645 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $666.00 | 12/18/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367647 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $25.00 | 12/18/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367649 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $72.00 | 12/18/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367653 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,825.00 | 12/18/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367655 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $86.00 | 12/18/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367657 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $366.00 | 12/18/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367659 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $460.00 | 12/18/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367661 |
| Principal investigator 1 | Roche Products Limited | $3,284.00 | 12/17/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598909 |
| Principal investigator 1 | Roche Products Limited | $3,223.00 | 12/17/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598913 |
| Principal investigator 1 | Roche Products Limited | $5,178.00 | 12/17/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598916 |
| Principal investigator 1 | Roche Products Limited | $4,640.00 | 12/17/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598920 |
| Principal investigator 1 | Roche Products Limited | $3,917.00 | 12/17/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598925 |
| Principal investigator 1 | Roche Products Limited | $1,345.00 | 12/17/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598929 |
| Principal investigator 1 | Roche Products Limited | $10,679.00 | 12/17/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598933 |
| Principal investigator 1 | Roche Products Limited | $3,003.00 | 12/17/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598940 |
| Principal investigator 1 | Roche Products Limited | $3,636.00 | 12/17/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598950 |
| Principal investigator 1 | Roche Products Limited | $2,713.00 | 12/17/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598958 |
| Principal investigator 1 | Roche Products Limited | $5,353.00 | 12/17/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598969 |
| Principal investigator 1 | Roche Products Limited | $8,250.00 | 12/17/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598973 |
| Principal investigator 1 | Roche Products Limited | $4,640.00 | 12/17/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598978 |
| Principal investigator 1 | Roche Products Limited | $2,128.00 | 12/17/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598981 |
| Principal investigator 1 | Roche Products Limited | $3,758.00 | 12/17/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598985 |
| Principal investigator 1 | Roche Products Limited | $2,857.00 | 12/17/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598989 |
| Principal investigator 1 | Roche Products Limited | $4,640.00 | 12/17/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211599002 |
| Principal investigator 1 | Roche Products Limited | $1,250.00 | 12/17/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211599007 |
| Principal investigator 1 | Roche Products Limited | $3,758.00 | 12/17/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211599011 |
| Principal investigator 1 | Genentech, Inc. | $9,355.00 | 12/15/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | INTRINSIC mCRC with specific genomic alterations | No dispute reported | 06/30/2026 | 1211598660 |
| Principal investigator 1 | Roche Products Limited | $820.00 | 12/10/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598900 |
| Principal investigator 1 | Roche Products Limited | $422.00 | 12/10/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598905 |
| Principal investigator 1 | Roche Products Limited | $2,393.00 | 12/10/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598935 |
| Principal investigator 1 | Roche Products Limited | $5,110.00 | 12/10/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598946 |
| Principal investigator 1 | Roche Products Limited | $5,731.00 | 12/10/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598955 |
| Principal investigator 1 | Roche Products Limited | $1,122.00 | 12/10/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598962 |
| Principal investigator 1 | Roche Products Limited | $880.00 | 12/10/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598966 |
| Principal investigator 1 | Roche Products Limited | $5,242.00 | 12/10/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598993 |
| Principal investigator 1 | Roche Products Limited | $2,459.00 | 12/10/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598998 |
| Principal investigator 1 | Roche Products Limited | $414.00 | 12/10/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211599015 |
| Principal investigator 1 | Genentech, Inc. | $1,380.00 | 12/08/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | INTRINSIC mCRC with specific genomic alterations | No dispute reported | 06/30/2026 | 1211598656 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,218.00 | 12/03/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367637 |
| Principal investigator 1 | PFIZER INC. | $4,124.58 | 11/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228729443 |
| Recipient | ABBVIE INC. | $1,812.00 | 11/20/2025 | Covered Recipient Physician | A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202401583 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,500.00 | 11/17/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192174421 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,325.00 | 11/17/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192174434 |
| Principal investigator 1 | ABBVIE INC. | $611.80 | 11/13/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202523931 |
| Principal investigator 1 | ABBVIE INC. | $611.80 | 11/13/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202523933 |
| Principal investigator 1 | ABBVIE INC. | $1,702.40 | 11/13/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202523935 |
| Principal investigator 1 | ABBVIE INC. | $611.80 | 11/13/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202523937 |
| Principal investigator 1 | ABBVIE INC. | $2,447.20 | 11/13/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202523939 |
| Principal investigator 1 | ABBVIE INC. | $611.80 | 11/13/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202523949 |
| Principal investigator 1 | ABBVIE INC. | $248.71 | 11/13/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202523953 |
| Principal investigator 1 | ABBVIE INC. | $250.00 | 11/13/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202523955 |
| Principal investigator 1 | ABBVIE INC. | $250.00 | 11/13/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202523959 |
| Principal investigator 1 | ABBVIE INC. | $1,702.40 | 11/13/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202523969 |
| Principal investigator 1 | ABBVIE INC. | $611.80 | 11/13/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202523971 |
| Principal investigator 1 | ABBVIE INC. | $248.71 | 11/13/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202523973 |
| Principal investigator 1 | ABBVIE INC. | $611.80 | 11/13/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202523975 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 11/13/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202523977 |
| Principal investigator 1 | ABBVIE INC. | $1,702.40 | 11/13/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202523979 |
| Principal investigator 1 | ABBVIE INC. | $611.80 | 11/13/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202523981 |
| Principal investigator 1 | ABBVIE INC. | $250.00 | 11/13/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202523983 |
| Principal investigator 1 | ABBVIE INC. | $611.80 | 11/13/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202523985 |
| Principal investigator 1 | ABBVIE INC. | $611.80 | 11/13/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202523987 |
| Principal investigator 1 | ABBVIE INC. | $250.00 | 11/13/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202523989 |
| Principal investigator 1 | ABBVIE INC. | $250.00 | 11/13/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202523991 |
| Principal investigator 1 | ABBVIE INC. | $611.80 | 11/13/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202523993 |
| Principal investigator 1 | ABBVIE INC. | $611.80 | 11/13/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202523995 |
| Principal investigator 1 | ABBVIE INC. | $27,728.43 | 11/05/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan | No dispute reported | 06/30/2026 | 1202521889 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,218.00 | 11/05/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367619 |
| Principal investigator 1 | ABBVIE INC. | $7,182.00 | 11/04/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab | No dispute reported | 06/30/2026 | 1202520391 |
| Principal investigator 1 | ABBVIE INC. | $3,653.51 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518979 |
| Principal investigator 1 | ABBVIE INC. | $2,649.36 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518981 |
| Principal investigator 1 | ABBVIE INC. | $3,040.38 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518983 |
| Principal investigator 1 | ABBVIE INC. | $2,649.36 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518985 |
| Principal investigator 1 | ABBVIE INC. | $3,733.31 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518989 |
| Principal investigator 1 | ABBVIE INC. | $3,733.31 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518991 |
| Principal investigator 1 | ABBVIE INC. | $2,036.23 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519007 |
| Principal investigator 1 | ABBVIE INC. | $3,653.51 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519009 |
| Principal investigator 1 | ABBVIE INC. | $3,653.51 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519019 |
| Principal investigator 1 | ABBVIE INC. | $3,733.31 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519055 |
| Principal investigator 1 | ABBVIE INC. | $3,040.38 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519065 |
| Principal investigator 1 | ABBVIE INC. | $3,653.51 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519071 |
| Principal investigator 1 | ABBVIE INC. | $2,036.23 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519089 |
| Principal investigator 1 | ABBVIE INC. | $3,653.51 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519121 |
| Principal investigator 1 | ABBVIE INC. | $3,040.38 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519123 |
| Principal investigator 1 | ABBVIE INC. | $2,649.36 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519125 |
| Principal investigator 1 | ABBVIE INC. | $2,036.23 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519127 |
| Principal investigator 1 | ABBVIE INC. | $3,653.51 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519129 |
| Principal investigator 1 | ABBVIE INC. | $3,733.31 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519143 |
| Principal investigator 1 | ABBVIE INC. | $3,653.51 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519149 |
| Principal investigator 1 | ABBVIE INC. | $3,733.31 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519151 |
| Principal investigator 1 | ABBVIE INC. | $2,649.36 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519157 |
| Principal investigator 1 | ABBVIE INC. | $3,653.51 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519159 |
| Principal investigator 1 | ABBVIE INC. | $2,036.23 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519161 |
| Principal investigator 1 | ABBVIE INC. | $3,066.98 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519185 |
| Principal investigator 1 | ABBVIE INC. | $3,040.38 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519187 |
| Principal investigator 1 | ABBVIE INC. | $3,040.38 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519203 |
| Principal investigator 1 | ABBVIE INC. | $3,653.51 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519219 |
| Principal investigator 1 | ABBVIE INC. | $3,653.51 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519259 |
| Principal investigator 1 | ABBVIE INC. | $3,040.38 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519261 |
| Principal investigator 1 | ABBVIE INC. | $3,653.51 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519265 |
| Principal investigator 1 | ABBVIE INC. | $3,653.51 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519267 |
| Principal investigator 1 | ABBVIE INC. | $2,649.36 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519327 |
| Principal investigator 1 | ABBVIE INC. | $6,927.97 | 10/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202519515 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,128.00 | 10/28/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192113096 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,250.00 | 10/28/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192113115 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,211.76 | 10/28/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192113134 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,713.00 | 10/28/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192174429 |
| Principal investigator 1 | ABBVIE INC. | $53.20 | 10/27/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518553 |
| Principal investigator 1 | ABBVIE INC. | $884.45 | 10/27/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518555 |
| Principal investigator 1 | ABBVIE INC. | $3,914.19 | 10/27/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518569 |
| Principal investigator 1 | ABBVIE INC. | $3,914.19 | 10/27/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518571 |
| Principal investigator 1 | ABBVIE INC. | $3,914.19 | 10/27/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518573 |
| Principal investigator 1 | ABBVIE INC. | $500.08 | 10/27/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518575 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,250.00 | 10/23/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192112925 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $226.00 | 10/23/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192112932 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $460.00 | 10/23/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192113085 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,325.00 | 10/23/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192113108 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,713.00 | 10/23/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192113164 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,500.00 | 10/23/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192113180 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $460.00 | 10/23/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192168364 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $226.00 | 10/23/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192168373 |
| Principal investigator 1 | ABBVIE INC. | $409.64 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517723 |
| Principal investigator 1 | ABBVIE INC. | $2,622.76 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517737 |
| Principal investigator 1 | ABBVIE INC. | $1,013.46 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517739 |
| Principal investigator 1 | ABBVIE INC. | $1,013.46 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517741 |
| Principal investigator 1 | ABBVIE INC. | $444.22 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517743 |
| Principal investigator 1 | ABBVIE INC. | $57.19 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517753 |
| Principal investigator 1 | ABBVIE INC. | $2,622.76 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517755 |
| Principal investigator 1 | ABBVIE INC. | $2,622.76 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517757 |
| Principal investigator 1 | ABBVIE INC. | $65.17 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517759 |
| Principal investigator 1 | ABBVIE INC. | $57.19 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517761 |
| Principal investigator 1 | ABBVIE INC. | $1,013.46 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517791 |
| Principal investigator 1 | ABBVIE INC. | $409.64 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517795 |
| Principal investigator 1 | ABBVIE INC. | $2,622.76 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517797 |
| Principal investigator 1 | ABBVIE INC. | $595.84 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517799 |
| Principal investigator 1 | ABBVIE INC. | $148.96 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517801 |
| Principal investigator 1 | ABBVIE INC. | $2,622.76 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517803 |
| Principal investigator 1 | ABBVIE INC. | $65.17 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517805 |
| Principal investigator 1 | ABBVIE INC. | $223.44 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517807 |
| Principal investigator 1 | ABBVIE INC. | $2,622.76 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517821 |
| Principal investigator 1 | ABBVIE INC. | $2,622.76 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517823 |
| Principal investigator 1 | ABBVIE INC. | $444.22 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517825 |
| Principal investigator 1 | ABBVIE INC. | $57.19 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517829 |
| Principal investigator 1 | ABBVIE INC. | $1,013.46 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517831 |
| Principal investigator 1 | ABBVIE INC. | $65.17 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517833 |
| Principal investigator 1 | ABBVIE INC. | $148.96 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517855 |
| Principal investigator 1 | ABBVIE INC. | $747.46 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517857 |
| Principal investigator 1 | ABBVIE INC. | $65.17 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517859 |
| Principal investigator 1 | ABBVIE INC. | $747.46 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517861 |
| Principal investigator 1 | ABBVIE INC. | $171.57 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517863 |
| Principal investigator 1 | ABBVIE INC. | $444.22 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517865 |
| Principal investigator 1 | ABBVIE INC. | $148.96 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517867 |
| Principal investigator 1 | ABBVIE INC. | $223.44 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517869 |
| Principal investigator 1 | ABBVIE INC. | $115.71 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517871 |
| Principal investigator 1 | ABBVIE INC. | $57.19 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517873 |
| Principal investigator 1 | ABBVIE INC. | $409.64 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517875 |
| Principal investigator 1 | ABBVIE INC. | $4,765.39 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517877 |
| Principal investigator 1 | ABBVIE INC. | $409.64 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517879 |
| Principal investigator 1 | ABBVIE INC. | $2,622.76 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517881 |
| Principal investigator 1 | ABBVIE INC. | $11,461.94 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517883 |
| Principal investigator 1 | ABBVIE INC. | $409.64 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517897 |
| Principal investigator 1 | ABBVIE INC. | $11,461.94 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517899 |
| Principal investigator 1 | ABBVIE INC. | $57.19 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517901 |
| Principal investigator 1 | ABBVIE INC. | $57.19 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517903 |
| Principal investigator 1 | ABBVIE INC. | $444.22 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517905 |
| Principal investigator 1 | ABBVIE INC. | $2,622.76 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517907 |
| Principal investigator 1 | ABBVIE INC. | $57.19 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517909 |
| Principal investigator 1 | ABBVIE INC. | $2,616.11 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517911 |
| Principal investigator 1 | ABBVIE INC. | $2,622.76 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517913 |
| Principal investigator 1 | ABBVIE INC. | $409.64 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517915 |
| Principal investigator 1 | ABBVIE INC. | $2,622.76 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517933 |
| Principal investigator 1 | ABBVIE INC. | $2,242.38 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517935 |
| Principal investigator 1 | ABBVIE INC. | $5,730.97 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517937 |
| Principal investigator 1 | ABBVIE INC. | $57.19 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517939 |
| Principal investigator 1 | ABBVIE INC. | $2,622.76 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517941 |
| Principal investigator 1 | ABBVIE INC. | $1,494.92 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517943 |
| Principal investigator 1 | ABBVIE INC. | $57.19 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517945 |
| Principal investigator 1 | ABBVIE INC. | $11,461.94 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517947 |
| Principal investigator 1 | ABBVIE INC. | $11,461.94 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517949 |
| Principal investigator 1 | ABBVIE INC. | $444.22 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517951 |
| Principal investigator 1 | ABBVIE INC. | $2,622.76 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517953 |
| Principal investigator 1 | ABBVIE INC. | $297.92 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517955 |
| Principal investigator 1 | ABBVIE INC. | $115.71 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517957 |
| Principal investigator 1 | ABBVIE INC. | $747.46 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517959 |
| Principal investigator 1 | ABBVIE INC. | $5,730.97 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517961 |
| Principal investigator 1 | ABBVIE INC. | $1,013.46 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517963 |
| Principal investigator 1 | ABBVIE INC. | $1,121.19 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517965 |
| Principal investigator 1 | ABBVIE INC. | $373.73 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517967 |
| Principal investigator 1 | ABBVIE INC. | $2,622.76 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517969 |
| Principal investigator 1 | ABBVIE INC. | $11,461.94 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517971 |
| Principal investigator 1 | ABBVIE INC. | $2,622.76 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517977 |
| Principal investigator 1 | ABBVIE INC. | $595.84 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517979 |
| Principal investigator 1 | ABBVIE INC. | $2,622.76 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517981 |
| Principal investigator 1 | ABBVIE INC. | $1,013.46 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517983 |
| Principal investigator 1 | ABBVIE INC. | $223.44 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517985 |
| Principal investigator 1 | ABBVIE INC. | $171.57 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517993 |
| Principal investigator 1 | ABBVIE INC. | $115.71 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517995 |
| Principal investigator 1 | ABBVIE INC. | $11,461.94 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202517997 |
| Principal investigator 1 | ABBVIE INC. | $2,622.76 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518001 |
| Principal investigator 1 | ABBVIE INC. | $506.73 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518003 |
| Principal investigator 1 | ABBVIE INC. | $11,461.94 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518005 |
| Principal investigator 1 | ABBVIE INC. | $409.64 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518007 |
| Principal investigator 1 | ABBVIE INC. | $2,622.76 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518037 |
| Principal investigator 1 | ABBVIE INC. | $2,622.76 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518039 |
| Principal investigator 1 | ABBVIE INC. | $506.73 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518041 |
| Principal investigator 1 | ABBVIE INC. | $57.19 | 10/22/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202518043 |
| Recipient | Amgen Inc. | $429.01 | 10/20/2025 | Covered Recipient Physician | A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigators Choice (Trifluridine and Tipiracil or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects with KRAS p.G12C Mutation | No dispute reported | 06/30/2026 | 1246636908 |
| Principal investigator 1 | ABBVIE INC. | $3,617.27 | 10/07/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1202513457 |
| Principal investigator 1 | PFIZER INC. | $4,124.58 | 10/06/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228730520 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,218.00 | 10/02/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367651 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $4,595.00 | 09/30/2025 | Non-covered Recipient Entity Duke University , | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190328579 |
| Principal investigator 1 | ABBVIE INC. | $1,094.59 | 09/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512616 |
| Principal investigator 1 | ABBVIE INC. | $6,927.97 | 09/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512648 |
| Principal investigator 1 | ABBVIE INC. | $6,927.97 | 09/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512650 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 09/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512656 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 09/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512658 |
| Principal investigator 1 | ABBVIE INC. | $3,747.94 | 09/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512672 |
| Principal investigator 1 | ABBVIE INC. | $6,927.97 | 09/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512674 |
| Principal investigator 1 | ABBVIE INC. | $6,927.97 | 09/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512694 |
| Principal investigator 1 | ABBVIE INC. | $6,927.97 | 09/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512704 |
| Principal investigator 1 | ABBVIE INC. | $994.84 | 09/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512454 |
| Principal investigator 1 | ABBVIE INC. | $460.00 | 09/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512456 |
| Principal investigator 1 | ABBVIE INC. | $3,258.50 | 09/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512460 |
| Principal investigator 1 | ABBVIE INC. | $332.50 | 09/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512462 |
| Principal investigator 1 | ABBVIE INC. | $2,984.52 | 09/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512464 |
| Principal investigator 1 | ABBVIE INC. | $2,984.52 | 09/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512466 |
| Principal investigator 1 | ABBVIE INC. | $332.50 | 09/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512470 |
| Principal investigator 1 | ABBVIE INC. | $2,984.52 | 09/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512472 |
| Principal investigator 1 | ABBVIE INC. | $2,984.52 | 09/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512474 |
| Principal investigator 1 | ABBVIE INC. | $332.50 | 09/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512476 |
| Principal investigator 1 | ABBVIE INC. | $2,984.52 | 09/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512478 |
| Principal investigator 1 | ABBVIE INC. | $2,984.52 | 09/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512480 |
| Principal investigator 1 | ABBVIE INC. | $332.50 | 09/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512484 |
| Principal investigator 1 | ABBVIE INC. | $332.50 | 09/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512486 |
| Principal investigator 1 | ABBVIE INC. | $3,258.50 | 09/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512488 |
| Principal investigator 1 | ABBVIE INC. | $3,258.50 | 09/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512490 |
| Principal investigator 1 | ABBVIE INC. | $332.50 | 09/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512492 |
| Principal investigator 1 | ABBVIE INC. | $332.50 | 09/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512494 |
| Principal investigator 1 | ABBVIE INC. | $3,258.50 | 09/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512496 |
| Principal investigator 1 | ABBVIE INC. | $2,984.52 | 09/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512504 |
| Principal investigator 1 | ABBVIE INC. | $2,984.52 | 09/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512506 |
| Principal investigator 1 | ABBVIE INC. | $2,984.52 | 09/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512508 |
| Principal investigator 1 | ABBVIE INC. | $2,984.52 | 09/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512510 |
| Principal investigator 1 | ABBVIE INC. | $2,984.52 | 09/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512512 |
| Principal investigator 1 | ABBVIE INC. | $3,258.50 | 09/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512514 |
| Principal investigator 1 | ABBVIE INC. | $2,984.52 | 09/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512516 |
| Principal investigator 1 | ABBVIE INC. | $2,210.00 | 09/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512518 |
| Principal investigator 1 | ABBVIE INC. | $3,258.50 | 09/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512520 |
| Principal investigator 1 | ABBVIE INC. | $248.71 | 09/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512048 |
| Principal investigator 1 | ABBVIE INC. | $248.71 | 09/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512050 |
| Principal investigator 1 | ABBVIE INC. | $1,731.99 | 09/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202512078 |
| Principal investigator 1 | PFIZER INC. | $32,997.51 | 09/22/2025 | Non-covered Recipient Entity Duke Cancer Center | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228718339 |
| Principal investigator 1 | PFIZER INC. | $10,940.00 | 09/22/2025 | Non-covered Recipient Entity Duke Cancer Center | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228718341 |
| Principal investigator 1 | PFIZER INC. | $10,940.00 | 09/19/2025 | Non-covered Recipient Entity Duke Cancer Center | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228716899 |
| Principal investigator 1 | PFIZER INC. | $32,997.51 | 09/19/2025 | Non-covered Recipient Entity Duke Cancer Center | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228716971 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,081.58 | 09/18/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192113090 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,445.17 | 09/18/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192113188 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $6,375.00 | 09/09/2025 | Non-covered Recipient Entity Duke University , | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190328583 |
| Principal investigator 1 | ABBVIE INC. | $2,971.22 | 09/03/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab | No dispute reported | 06/30/2026 | 1202508074 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,218.00 | 09/03/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367609 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,218.00 | 09/03/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367611 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,218.00 | 09/03/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367613 |
| Principal investigator 1 | ABBVIE INC. | $2,491.09 | 09/01/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202506767 |
| Principal investigator 1 | ABBVIE INC. | $2,036.23 | 08/07/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202503679 |
| Principal investigator 1 | ABBVIE INC. | $2,036.23 | 08/07/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202503681 |
| Principal investigator 1 | ABBVIE INC. | $2,036.23 | 08/07/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202503691 |
| Principal investigator 1 | ABBVIE INC. | $1,556.10 | 08/05/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab | No dispute reported | 06/30/2026 | 1202501694 |
| Principal investigator 1 | ABBVIE INC. | $4,040.50 | 08/04/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202500928 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,218.00 | 08/01/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367615 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $8,555.00 | 07/29/2025 | Non-covered Recipient Entity Duke University , | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190328581 |
| Principal investigator 1 | ABBVIE INC. | $3,747.94 | 07/28/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202500002 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $6,755.87 | 07/21/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192113174 |
| Principal investigator 1 | ABBVIE INC. | $5,745.60 | 07/08/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab | No dispute reported | 06/30/2026 | 1202497144 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $118,200.00 | 07/03/2025 | Non-covered Recipient Entity Duke University | A Phase 1,2, Open-Label, Dose Escalation and Expansion Study with PT886 followed by a Multi-cohorT Study in Patients With Advanced GastrIc, Gastroesophageal JuNction GEJ, or Pancreatic Ductal AdEnocarcinomas of PT886, in Combination with either ChemotherApy, and,or the ChecKpoint Inhibitor Pembrolizumab. TWINPEAK Study | No dispute reported | 06/30/2026 | 1232936160 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,218.00 | 07/02/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367617 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $99,521.00 | 07/01/2025 | Non-covered Recipient Entity Duke University , | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190332663 |
| Principal investigator 1 | ABBVIE INC. | $3,368.89 | 06/27/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493481 |
| Principal investigator 1 | ABBVIE INC. | $1,246.72 | 06/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493039 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 06/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493041 |
| Principal investigator 1 | ABBVIE INC. | $1,246.72 | 06/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493043 |
| Principal investigator 1 | ABBVIE INC. | $1,246.72 | 06/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493047 |
| Principal investigator 1 | ABBVIE INC. | $1,246.72 | 06/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493049 |
| Principal investigator 1 | ABBVIE INC. | $1,352.61 | 06/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493051 |
| Principal investigator 1 | ABBVIE INC. | $1,246.72 | 06/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493053 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 06/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493055 |
| Principal investigator 1 | ABBVIE INC. | $1,246.72 | 06/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493057 |
| Principal investigator 1 | ABBVIE INC. | $1,246.72 | 06/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493059 |
| Principal investigator 1 | ABBVIE INC. | $1,352.61 | 06/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493061 |
| Principal investigator 1 | ABBVIE INC. | $3,747.94 | 06/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493063 |
| Principal investigator 1 | ABBVIE INC. | $1,246.72 | 06/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493065 |
| Principal investigator 1 | ABBVIE INC. | $3,747.94 | 06/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493067 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 06/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493069 |
| Principal investigator 1 | ABBVIE INC. | $1,246.72 | 06/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493071 |
| Principal investigator 1 | ABBVIE INC. | $3,747.94 | 06/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493073 |
| Principal investigator 1 | ABBVIE INC. | $884.45 | 06/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493089 |
| Principal investigator 1 | ABBVIE INC. | $1,246.72 | 06/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493091 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 06/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493093 |
| Principal investigator 1 | ABBVIE INC. | $1,246.72 | 06/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493115 |
| Principal investigator 1 | ABBVIE INC. | $884.45 | 06/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493117 |
| Principal investigator 1 | ABBVIE INC. | $3,747.94 | 06/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493119 |
| Principal investigator 1 | ABBVIE INC. | $551.95 | 06/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493121 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 06/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493123 |
| Principal investigator 1 | ABBVIE INC. | $1,246.72 | 06/26/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202493137 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $834.11 | 06/24/2025 | Non-covered Recipient Entity Duke University | DS8201-A-U207 | No dispute reported | 06/30/2026 | 1223367765 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,685.71 | 06/24/2025 | Non-covered Recipient Entity Duke University | DS8201-A-U207 | No dispute reported | 06/30/2026 | 1223367767 |
| Principal investigator 1 | ABBVIE INC. | $4,473.54 | 06/20/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202492529 |
| Principal investigator 1 | BeOne Medicines Ltd. | $17,993.00 | 06/17/2025 | Non-covered Recipient Entity Duke University , | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190330999 |
| Principal investigator 1 | PFIZER INC. | $2,394.00 | 06/16/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 1B2 DOSE ESCALATION AND EXPANSION STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND OXALIPLATINBASED CHEMOTHERAPY OR PEMBROLIZUMABCONTAINING COMBINATIONS FOR HER2 GASTROINTESTINAL CANCERS | No dispute reported | 06/30/2026 | 1228793140 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,565.36 | 06/13/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192174439 |
| Principal investigator 1 | PFIZER INC. | $6,252.50 | 06/09/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228778296 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $22,167.60 | 06/05/2025 | Non-covered Recipient Entity Duke University | DS8201-A-U207 | No dispute reported | 06/30/2026 | 1223367763 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,202.32 | 06/05/2025 | Non-covered Recipient Entity Duke University | DS8201-A-U207 | No dispute reported | 06/30/2026 | 1223367769 |
| Principal investigator 1 | ABBVIE INC. | $8,877.75 | 06/03/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab | No dispute reported | 06/30/2026 | 1202488551 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,218.00 | 06/02/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367605 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,218.00 | 06/02/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367607 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $74,964.25 | 05/31/2025 | Covered Recipient Teaching Hospital Duke University Hospital | Expansion of the Duke Molecular Tumor Board to community oncology sites across theSoutheast to support adoption of comprehensive genomic profiling and biomarker driventherapy selection for lung and thyroid cancer patients | No dispute reported | 06/30/2026 | 1211415095 |
| Principal investigator 1 | BeOne Medicines Ltd. | $14,006.00 | 05/30/2025 | Non-covered Recipient Entity Duke University , | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190330997 |
| Principal investigator 1 | BeOne Medicines Ltd. | $2,976.00 | 05/30/2025 | Non-covered Recipient Entity Duke University , | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190331459 |
| Principal investigator 1 | Eli Lilly and Company | $247,981.69 | 05/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 1A/1B TRIAL OF LY3962673 IN PARTICIPANTS WITH KRAS G12D-MUTANT SOLID TUMORS | No dispute reported | 06/30/2026 | 1187881378 |
| Principal investigator 1 | Genentech, Inc. | $3,450.00 | 05/28/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | INTRINSIC mCRC with specific genomic alterations | No dispute reported | 06/30/2026 | 1211598651 |
| Principal investigator 1 | ABBVIE INC. | $1,954.77 | 05/27/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1202486271 |
| Principal investigator 1 | ABBVIE INC. | $1,954.77 | 05/27/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1202486273 |
| Principal investigator 1 | ABBVIE INC. | $3,000.00 | 05/27/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1202486275 |
| Principal investigator 1 | ABBVIE INC. | $1,954.77 | 05/27/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1202486277 |
| Principal investigator 1 | Genentech, Inc. | $2,445.00 | 05/23/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | 1L Biliary Tract Cancer | No dispute reported | 06/30/2026 | 1211598664 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $22,858.16 | 05/22/2025 | Non-covered Recipient Entity Duke University | DS8201-A-U207 | No dispute reported | 06/30/2026 | 1223367761 |
| Principal investigator 1 | Genentech, Inc. | $446.07 | 05/19/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | 1L Biliary Tract Cancer | No dispute reported | 06/30/2026 | 1211598313 |
| Principal investigator 1 | Eli Lilly and Company | $74,102.38 | 05/15/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 1A/1B STUDY OF THE PAN-KRAS INHIBITOR LY4066434 IN PARTICIPANTS WITH KRAS MUTANT SOLID TUMORS | No dispute reported | 06/30/2026 | 1187879873 |
| Principal investigator 1 | BeiGene, Ltd. | $56,092.00 | 05/09/2025 | Non-covered Recipient Entity Duke University , | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190324006 |
| Principal investigator 1 | Genentech, Inc. | $2,870.00 | 05/09/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598458 |
| Principal investigator 1 | Genentech, Inc. | $1,345.00 | 05/09/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598462 |
| Principal investigator 1 | Genentech, Inc. | $10,679.00 | 05/09/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598466 |
| Principal investigator 1 | Genentech, Inc. | $8,250.00 | 05/09/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598470 |
| Principal investigator 1 | Genentech, Inc. | $3,758.00 | 05/09/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598474 |
| Principal investigator 1 | Genentech, Inc. | $2,857.00 | 05/09/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598478 |
| Principal investigator 1 | Genentech, Inc. | $4,640.00 | 05/09/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598482 |
| Principal investigator 1 | Genentech, Inc. | $1,345.00 | 05/09/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598486 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480083 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480085 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480087 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480099 |
| Principal investigator 1 | ABBVIE INC. | $551.95 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480101 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480103 |
| Principal investigator 1 | ABBVIE INC. | $3,653.51 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480105 |
| Principal investigator 1 | ABBVIE INC. | $4,072.46 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480107 |
| Principal investigator 1 | ABBVIE INC. | $6,927.97 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480109 |
| Principal investigator 1 | ABBVIE INC. | $3,922.17 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480111 |
| Principal investigator 1 | ABBVIE INC. | $6,344.10 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480113 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480123 |
| Principal investigator 1 | ABBVIE INC. | $3,733.31 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480125 |
| Principal investigator 1 | ABBVIE INC. | $3,653.51 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480127 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480133 |
| Principal investigator 1 | ABBVIE INC. | $3,653.51 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480135 |
| Principal investigator 1 | ABBVIE INC. | $4,482.10 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480137 |
| Principal investigator 1 | ABBVIE INC. | $2,036.23 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480143 |
| Principal investigator 1 | ABBVIE INC. | $3,733.31 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480145 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480147 |
| Principal investigator 1 | ABBVIE INC. | $3,653.51 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480149 |
| Principal investigator 1 | ABBVIE INC. | $3,653.51 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480151 |
| Principal investigator 1 | ABBVIE INC. | $762.09 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480157 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480159 |
| Principal investigator 1 | ABBVIE INC. | $1,094.59 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480161 |
| Principal investigator 1 | ABBVIE INC. | $884.45 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480163 |
| Principal investigator 1 | ABBVIE INC. | $6,344.10 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480165 |
| Principal investigator 1 | ABBVIE INC. | $2,649.36 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480167 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480181 |
| Principal investigator 1 | ABBVIE INC. | $3,733.31 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480183 |
| Principal investigator 1 | ABBVIE INC. | $4,482.10 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480185 |
| Principal investigator 1 | ABBVIE INC. | $2,036.23 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480187 |
| Principal investigator 1 | ABBVIE INC. | $884.45 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480391 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480393 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480397 |
| Principal investigator 1 | ABBVIE INC. | $2,036.23 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480399 |
| Principal investigator 1 | ABBVIE INC. | $2,491.09 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480401 |
| Principal investigator 1 | ABBVIE INC. | $4,072.46 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480403 |
| Principal investigator 1 | ABBVIE INC. | $3,040.38 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480411 |
| Principal investigator 1 | ABBVIE INC. | $3,040.38 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480413 |
| Principal investigator 1 | ABBVIE INC. | $3,314.36 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480415 |
| Principal investigator 1 | ABBVIE INC. | $3,314.36 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480417 |
| Principal investigator 1 | ABBVIE INC. | $3,314.36 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480419 |
| Principal investigator 1 | ABBVIE INC. | $4,072.46 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480421 |
| Principal investigator 1 | ABBVIE INC. | $2,649.36 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480429 |
| Principal investigator 1 | ABBVIE INC. | $4,482.10 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480431 |
| Principal investigator 1 | ABBVIE INC. | $3,040.38 | 04/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202480433 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,218.00 | 04/25/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367601 |
| Principal investigator 1 | Amgen Inc. | $44,623.45 | 04/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-nave Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301) | No dispute reported | 06/30/2026 | 1246640967 |
| Principal investigator 1 | BeiGene, Ltd. | $18,601.00 | 04/21/2025 | Non-covered Recipient Entity Duke University , | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190324008 |
| Principal investigator 1 | PFIZER INC. | $10,940.00 | 04/16/2025 | Non-covered Recipient Entity Duke Cancer Center | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228755010 |
| Principal investigator 1 | PFIZER INC. | $10,940.00 | 04/15/2025 | Non-covered Recipient Entity Duke Cancer Center | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228756295 |
| Recipient | ABBVIE INC. | $1,268.75 | 04/14/2025 | Covered Recipient Physician | A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | No dispute reported | 06/30/2026 | 1202401579 |
| Principal investigator 1 | PFIZER INC. | $16,810.74 | 04/07/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228792009 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,218.00 | 04/02/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367603 |
| Principal investigator 1 | ABBVIE INC. | $1,834.07 | 03/31/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467341 |
| Principal investigator 1 | ABBVIE INC. | $2,327.50 | 03/31/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467345 |
| Principal investigator 1 | ABBVIE INC. | $1,292.76 | 03/31/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467349 |
| Principal investigator 1 | ABBVIE INC. | $3,767.89 | 03/31/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467353 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 03/31/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467357 |
| Principal investigator 1 | ABBVIE INC. | $4,822.58 | 03/31/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467360 |
| Principal investigator 1 | ABBVIE INC. | $1,121.19 | 03/31/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467365 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 03/31/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467368 |
| Principal investigator 1 | ABBVIE INC. | $2,380.70 | 03/31/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467429 |
| Principal investigator 1 | ABBVIE INC. | $2,327.50 | 03/31/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467433 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 03/31/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467437 |
| Principal investigator 1 | ABBVIE INC. | $1,121.19 | 03/31/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467442 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 03/31/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467619 |
| Principal investigator 1 | ABBVIE INC. | $1,318.03 | 03/31/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467623 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 03/31/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467640 |
| Principal investigator 1 | ABBVIE INC. | $2,327.50 | 03/31/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467643 |
| Principal investigator 1 | ABBVIE INC. | $1,352.61 | 03/31/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467677 |
| Principal investigator 1 | ABBVIE INC. | $1,352.61 | 03/31/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202467681 |
| Principal investigator 1 | ABBVIE INC. | $4,282.60 | 03/25/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202465962 |
| Principal investigator 1 | ABBVIE INC. | $497.42 | 03/25/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202465974 |
| Principal investigator 1 | ABBVIE INC. | $250.00 | 03/25/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202466056 |
| Principal investigator 1 | ABBVIE INC. | $1,246.72 | 03/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202465557 |
| Principal investigator 1 | ABBVIE INC. | $1,246.72 | 03/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202465561 |
| Principal investigator 1 | ABBVIE INC. | $1,246.72 | 03/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202465565 |
| Principal investigator 1 | ABBVIE INC. | $1,246.72 | 03/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202465569 |
| Principal investigator 1 | ABBVIE INC. | $1,246.72 | 03/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202465573 |
| Principal investigator 1 | ABBVIE INC. | $1,246.72 | 03/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202465577 |
| Principal investigator 1 | ABBVIE INC. | $1,246.72 | 03/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202465580 |
| Principal investigator 1 | ABBVIE INC. | $1,246.72 | 03/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202465584 |
| Principal investigator 1 | ABBVIE INC. | $13.30 | 03/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202465588 |
| Principal investigator 1 | ABBVIE INC. | $176.89 | 03/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202465618 |
| Principal investigator 1 | ABBVIE INC. | $1,246.72 | 03/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202465633 |
| Principal investigator 1 | ABBVIE INC. | $1,246.72 | 03/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202465638 |
| Principal investigator 1 | ABBVIE INC. | $1,246.72 | 03/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202465642 |
| Principal investigator 1 | ABBVIE INC. | $1,246.72 | 03/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202465646 |
| Principal investigator 1 | BeiGene, Ltd. | $14,180.00 | 03/24/2025 | Non-covered Recipient Entity Duke University , | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190324002 |
| Principal investigator 1 | Genentech, Inc. | $1,279.23 | 03/20/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | INTRINSIC mCRC with specific genomic alterations | No dispute reported | 06/30/2026 | 1211598309 |
| Principal investigator 1 | ABBVIE INC. | $920.00 | 03/19/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202464409 |
| Principal investigator 1 | ABBVIE INC. | $248.71 | 03/19/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202464413 |
| Principal investigator 1 | ABBVIE INC. | $3,710.00 | 03/19/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202464417 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $12,069.56 | 03/13/2025 | Non-covered Recipient Entity Duke University | DS8201-A-U207 | No dispute reported | 06/30/2026 | 1223367751 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,695.00 | 03/13/2025 | Non-covered Recipient Entity Duke University | DS8201-A-U207 | No dispute reported | 06/30/2026 | 1223367755 |
| Principal investigator 1 | BeiGene, Ltd. | $55,740.00 | 03/10/2025 | Non-covered Recipient Entity Duke University , | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190324004 |
| Principal investigator 1 | PFIZER INC. | $7,350.00 | 03/10/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 1B2 DOSE ESCALATION AND EXPANSION STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND OXALIPLATINBASED CHEMOTHERAPY OR PEMBROLIZUMABCONTAINING COMBINATIONS FOR HER2 GASTROINTESTINAL CANCERS | No dispute reported | 06/30/2026 | 1228787697 |
| Principal investigator 1 | PFIZER INC. | $13,500.00 | 03/10/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 1B2 DOSE ESCALATION AND EXPANSION STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND OXALIPLATINBASED CHEMOTHERAPY OR PEMBROLIZUMABCONTAINING COMBINATIONS FOR HER2 GASTROINTESTINAL CANCERS | No dispute reported | 06/30/2026 | 1228795449 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,330.00 | 03/07/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192113128 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $750.00 | 03/07/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192113140 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $7,182.00 | 03/07/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192113168 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,788.00 | 03/07/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192168360 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $7,448.00 | 03/07/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192168383 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,500.00 | 03/07/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192168387 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,500.00 | 03/07/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192174443 |
| Principal investigator 1 | ABBVIE INC. | $53.20 | 03/06/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202458936 |
| Principal investigator 1 | ABBVIE INC. | $82.46 | 03/06/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202458939 |
| Principal investigator 1 | ABBVIE INC. | $481.46 | 03/06/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202458943 |
| Principal investigator 1 | ABBVIE INC. | $180.88 | 03/06/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202458948 |
| Principal investigator 1 | ABBVIE INC. | $406.98 | 03/06/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202458960 |
| Principal investigator 1 | ABBVIE INC. | $46.55 | 03/06/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202458963 |
| Principal investigator 1 | ABBVIE INC. | $481.46 | 03/06/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202458971 |
| Principal investigator 1 | ABBVIE INC. | $239.40 | 03/06/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202458974 |
| Principal investigator 1 | ABBVIE INC. | $166.25 | 03/06/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202458979 |
| Principal investigator 1 | ABBVIE INC. | $59.85 | 03/06/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202458981 |
| Principal investigator 1 | ABBVIE INC. | $66.50 | 03/06/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202458985 |
| Principal investigator 1 | ABBVIE INC. | $2,451.19 | 03/05/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202455994 |
| Principal investigator 1 | ABBVIE INC. | $4,482.10 | 03/05/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202455998 |
| Principal investigator 1 | ABBVIE INC. | $6,927.97 | 03/05/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202456009 |
| Principal investigator 1 | ABBVIE INC. | $2,447.20 | 03/05/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202456013 |
| Principal investigator 1 | ABBVIE INC. | $6,927.97 | 03/05/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202456063 |
| Principal investigator 1 | ABBVIE INC. | $2,984.52 | 03/05/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202456156 |
| Principal investigator 1 | ABBVIE INC. | $1,596.00 | 03/05/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202456159 |
| Principal investigator 1 | ABBVIE INC. | $4,072.46 | 03/05/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202456163 |
| Principal investigator 1 | ABBVIE INC. | $6,927.97 | 03/05/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202456168 |
| Principal investigator 1 | ABBVIE INC. | $2,491.09 | 03/05/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202456171 |
| Principal investigator 1 | ABBVIE INC. | $4,482.10 | 03/05/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202456175 |
| Principal investigator 1 | ABBVIE INC. | $4,072.46 | 03/05/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202456179 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,218.00 | 03/05/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367593 |
| Principal investigator 1 | PFIZER INC. | $520.00 | 03/03/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 1B2 DOSE ESCALATION AND EXPANSION STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND OXALIPLATINBASED CHEMOTHERAPY OR PEMBROLIZUMABCONTAINING COMBINATIONS FOR HER2 GASTROINTESTINAL CANCERS | No dispute reported | 06/30/2026 | 1228795436 |
| Principal investigator 1 | Roche Products Limited | $1,500.00 | 03/03/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598534 |
| Principal investigator 1 | Roche Products Limited | $678.00 | 03/03/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598544 |
| Principal investigator 1 | Roche Products Limited | $3,325.00 | 03/03/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598567 |
| Principal investigator 1 | ABBVIE INC. | $10,687.00 | 02/27/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | M24-311 - Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab | No dispute reported | 06/30/2026 | 1202454397 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,713.00 | 02/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192112915 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,250.00 | 02/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192112921 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $226.00 | 02/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192112938 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,713.00 | 02/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192112943 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $226.00 | 02/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192112949 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,250.00 | 02/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192112954 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,713.00 | 02/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192112960 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,250.00 | 02/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192113103 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,250.00 | 02/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192113122 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,000.00 | 02/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192113147 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $226.00 | 02/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192113152 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $226.00 | 02/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192113158 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $226.00 | 02/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192168368 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,250.00 | 02/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192168376 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,713.00 | 02/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192174425 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,713.00 | 02/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M | No dispute reported | 06/30/2026 | 1192174448 |
| Principal investigator 1 | Roche Products Limited | $1,345.00 | 02/24/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598584 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,798.56 | 02/20/2025 | Non-covered Recipient Entity Duke University | DS8201-A-U207 | No dispute reported | 06/30/2026 | 1223367753 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,645.24 | 02/20/2025 | Non-covered Recipient Entity Duke University | DS8201-A-U207 | No dispute reported | 06/30/2026 | 1223367757 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,897.09 | 02/20/2025 | Non-covered Recipient Entity Duke University | DS8201-A-U207 | No dispute reported | 06/30/2026 | 1223367759 |
| Principal investigator 1 | PFIZER INC. | $31,493.56 | 02/18/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228796887 |
| Principal investigator 1 | PFIZER INC. | $7,500.00 | 02/10/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 1B2 DOSE ESCALATION AND EXPANSION STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND OXALIPLATINBASED CHEMOTHERAPY OR PEMBROLIZUMABCONTAINING COMBINATIONS FOR HER2 GASTROINTESTINAL CANCERS | No dispute reported | 06/30/2026 | 1228793787 |
| Principal investigator 1 | PFIZER INC. | $260.00 | 02/10/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A PHASE 1B2 DOSE ESCALATION AND EXPANSION STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND OXALIPLATINBASED CHEMOTHERAPY OR PEMBROLIZUMABCONTAINING COMBINATIONS FOR HER2 GASTROINTESTINAL CANCERS | No dispute reported | 06/30/2026 | 1228795961 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 02/05/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202446492 |
| Principal investigator 1 | ABBVIE INC. | $750.00 | 02/05/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202446507 |
| Principal investigator 1 | ABBVIE INC. | $4,894.40 | 02/05/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202446511 |
| Principal investigator 1 | ABBVIE INC. | $960.00 | 02/05/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202446515 |
| Principal investigator 1 | PFIZER INC. | $32,997.51 | 02/04/2025 | Non-covered Recipient Entity Duke Cancer Center | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228755013 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,218.00 | 02/03/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367595 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,218.00 | 02/03/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367599 |
| Principal investigator 1 | PFIZER INC. | $32,997.51 | 02/03/2025 | Non-covered Recipient Entity Duke Cancer Center | AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228756757 |
| Principal investigator 1 | ABBVIE INC. | $3,840.00 | 01/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202443258 |
| Principal investigator 1 | ABBVIE INC. | $460.00 | 01/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202443312 |
| Principal investigator 1 | ABBVIE INC. | $5,000.00 | 01/30/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202443321 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442056 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442060 |
| Principal investigator 1 | ABBVIE INC. | $1,218.28 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442064 |
| Principal investigator 1 | ABBVIE INC. | $762.09 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442096 |
| Principal investigator 1 | ABBVIE INC. | $1,820.77 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442100 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442104 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442109 |
| Principal investigator 1 | ABBVIE INC. | $1,218.28 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442407 |
| Principal investigator 1 | ABBVIE INC. | $884.45 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442410 |
| Principal investigator 1 | ABBVIE INC. | $4,482.10 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442413 |
| Principal investigator 1 | ABBVIE INC. | $4,482.10 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442417 |
| Principal investigator 1 | ABBVIE INC. | $4,072.46 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442442 |
| Principal investigator 1 | ABBVIE INC. | $2,036.23 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442446 |
| Principal investigator 1 | ABBVIE INC. | $960.00 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442636 |
| Principal investigator 1 | ABBVIE INC. | $3,571.05 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442727 |
| Principal investigator 1 | ABBVIE INC. | $4,482.10 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442730 |
| Principal investigator 1 | ABBVIE INC. | $3,571.05 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442749 |
| Principal investigator 1 | ABBVIE INC. | $3,747.94 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442753 |
| Principal investigator 1 | ABBVIE INC. | $1,094.59 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442757 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442761 |
| Principal investigator 1 | ABBVIE INC. | $6,344.10 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442765 |
| Principal investigator 1 | ABBVIE INC. | $4,482.10 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442769 |
| Principal investigator 1 | ABBVIE INC. | $3,653.51 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442773 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442776 |
| Principal investigator 1 | ABBVIE INC. | $884.45 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442779 |
| Principal investigator 1 | ABBVIE INC. | $6,927.97 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442783 |
| Principal investigator 1 | ABBVIE INC. | $1,602.65 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442786 |
| Principal investigator 1 | ABBVIE INC. | $884.45 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442790 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442795 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442799 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442815 |
| Principal investigator 1 | ABBVIE INC. | $4,482.10 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442819 |
| Principal investigator 1 | ABBVIE INC. | $3,747.94 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442823 |
| Principal investigator 1 | ABBVIE INC. | $1,218.28 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442826 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442830 |
| Principal investigator 1 | ABBVIE INC. | $762.09 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442833 |
| Principal investigator 1 | ABBVIE INC. | $3,584.35 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442837 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442846 |
| Principal investigator 1 | ABBVIE INC. | $1,218.28 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442850 |
| Principal investigator 1 | ABBVIE INC. | $3,922.17 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442854 |
| Principal investigator 1 | ABBVIE INC. | $2,649.36 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442859 |
| Principal investigator 1 | ABBVIE INC. | $3,584.35 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442864 |
| Principal investigator 1 | ABBVIE INC. | $4,482.10 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442867 |
| Principal investigator 1 | ABBVIE INC. | $551.95 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442871 |
| Principal investigator 1 | ABBVIE INC. | $551.95 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442876 |
| Principal investigator 1 | ABBVIE INC. | $2,501.22 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442889 |
| Principal investigator 1 | ABBVIE INC. | $4,482.10 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442893 |
| Principal investigator 1 | ABBVIE INC. | $1,250.00 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442896 |
| Principal investigator 1 | ABBVIE INC. | $551.95 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442900 |
| Principal investigator 1 | ABBVIE INC. | $884.45 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442905 |
| Principal investigator 1 | ABBVIE INC. | $4,482.10 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442909 |
| Principal investigator 1 | ABBVIE INC. | $4,482.10 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 1202442913 |
| Principal investigator 1 | Amgen Inc. | $240,898.77 | 01/29/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Sotorasib (AMG 510) Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and Sotorasib (AMG 510) Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreaK 100) | No dispute reported | 06/30/2026 | 1246640929 |
| Principal investigator 1 | BeiGene, Ltd. | $4,878.00 | 01/21/2025 | Non-covered Recipient Entity Duke University , | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190324888 |
| Principal investigator 1 | BeiGene, Ltd. | $7,354.00 | 01/21/2025 | Non-covered Recipient Entity Duke University , | A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | No dispute reported | 06/30/2026 | 1190324890 |
| Principal investigator 1 | ABBVIE INC. | $24,478.43 | 01/15/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | M24-064 - A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1202438617 |
| Principal investigator 1 | Amgen Inc. | $806,134.89 | 01/03/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) | No dispute reported | 06/30/2026 | 1246640935 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,218.00 | 01/03/2025 | Non-covered Recipient Entity Duke University | ROMAST-001 | No dispute reported | 06/30/2026 | 1223367597 |
| Principal investigator 1 | Roche Products Limited | $1,345.00 | 01/03/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598531 |
| Principal investigator 1 | Roche Products Limited | $4,353.00 | 01/03/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598539 |
| Principal investigator 1 | Roche Products Limited | $4,788.00 | 01/03/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598549 |
| Principal investigator 1 | Roche Products Limited | $14,630.00 | 01/03/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598553 |
| Principal investigator 1 | Roche Products Limited | $5,178.00 | 01/03/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598557 |
| Principal investigator 1 | Roche Products Limited | $399.00 | 01/03/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598562 |
| Principal investigator 1 | Roche Products Limited | $3,000.00 | 01/03/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598571 |
| Principal investigator 1 | Roche Products Limited | $1,110.55 | 01/03/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598575 |
| Principal investigator 1 | Roche Products Limited | $8,250.00 | 01/03/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598581 |
| Principal investigator 1 | Roche Products Limited | $904.00 | 01/03/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | EiH study with WRNinh in MSI dMMR advanced solid tumors | No dispute reported | 06/30/2026 | 1211598588 |
| Principal investigator 1 | Amgen Inc. | $419,511.88 | 01/02/2025 | Non-covered Recipient Entity DUKE CANCER CENTER | Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-nave Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301) | No dispute reported | 06/30/2026 | 1246640897 |